The UK National Screening Committee is re-examining whether screening adults for depression in primary care actually improves their health, after previous reviews found insufficient evidence to support routine screening. This matters because depression affects an estimated 280 million people worldwide, yet many cases go undetected when patients present with physical symptoms rather than low mood. Screening questionnaires could theoretically catch these hidden cases and allow earlier treatment, potentially preventing mild depression from becoming severe. But the UK NSC’s 2014 and 2020 reviews found no clear evidence that population-level screening reduces illness or death. This evidence map will systematically search for new research published since then to see whether that picture has changed. If the map uncovers strong new evidence that screening leads to better long-term outcomes—such as reduced symptoms, improved quality of life, or lower mortality—it could prompt the UK NSC to recommend routine depression screening in primary care. That would change how millions of adults are assessed for mental health problems during routine GP visits. If the evidence remains weak, the current policy of not screening will stand, and resources can focus on other approaches to identifying depression.
View original technical description
Background: Depression is a common mental health disorder that impairs functioning and quality of life. In 2019, an estimated 280 million people worldwide were affected, and prevalence is expected to remain high through 2030. Recognising depression can be challenging due to patient, provider, and system-level barriers, particularly when individuals present with somatic or nonspecific symptoms rather than classic low mood. Screening questionnaires can be a useful tool in primary care to help identify undiagnosed cases of depression, potentially leading to reduce progression from mild to severe forms through earlier treatment. However, previous reviews commissioned by the UK National Screening Committee (UK NSC) in 2014 and 2020 found insufficient evidence that population-level depression screening reduces morbidity or mortality, and routine screening was not recommended. The UK NSC has now commissioned an evidence map to identify new research on whether screening (population or targeted) for depression in adults leads to beneficial outcomes. Objective: The evidence map was designed to answer the following questions: Question 1. What is the volume and type of evidence that treatment for people diagnosed with mild or subthreshold depression through screening (population and targeted) leads to better outcomes in the longer term (beyond 2 years) than treatment for people diagnosed with mild or subthreshold depression through other methods? Question 2. What is the volume and type of evidence that screening (population and targeted) adults for depression reduces mortality and morbidity? Methods: The evidence map will follow the UK NSC assessment framework. Systematic literature searches will be conducted in EMBASE, PsycInfo, and the Cochrane Database of Systematic Reviews using depression-related terms to capture evidence relevant to both questions. Records retrieved will be imported into EndNote, deduplicated, and screened in Covidence by a single reviewer at title and abstract level. Full texts will not generally be assessed, but if a decision cannot be made from the title and abstract alone, and the number of publications is manageable, they will be reviewed. For Question 1, eligible studies must assess outcomes after pharmacological and/or non-pharmacological treatment of mild or subthreshold depression identified through screening versus other methods of detecting depression, with follow-up of =1 year. For Question 2, eligible studies will compare the offer of screening versus no screening, reporting outcomes such as depression symptoms, severity, chronicity, quality of life, mortality, or reported depression rates. Conclusion: This evidence map will provide an up-to-date overview of the available research on the effectiveness and outcomes of depression screening in adults. By identifying the volume and type of recent evidence, the findings will help determine whether new data justify a more detailed assessment of screening for depression by the UK NSC.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know